Objective:To preliminarily observe the clinical efficacy of microwave hyperthermia combined with intensity-modulated radiotherapy (IMRT) and chemotherapy for patients with locally advanced gastric cancer.Methods:Forty patients who could not been operated or refused operation were enrolled in this clinical trial, who were confirmed as locally advanced proximal or distal gastric cancer by gastroscopy pathology and imaging. Radiotherapy was delivered by IMRT technology for 5 times per week with a total dose of 46 to 56 Gy (median dose of 50 Gy) in 25 to 28 fractions. Synchronous hyperthermia was given at 42 to 44℃ twice a week, 45 min/time. S-1 or capecitabine-based synchronous chemotherapy was performed, d1-14/3 weeks. The symptom remission rate, adverse reactions, objective remission rate (complete and partial remission) and survival were observed.Results:A total of 40 patients, aged between 56 and 83 years (median age of 71 years), were enrolled in this study. The male-to-female ratio was 7: 1. Among them, 38 cases (95%) showed symptom remission. The most common adverse reactions were grade 1-2 gastrointestinal reactions and leukopenia. The objective remission rate was 87.5%, the 2-year progression-free survival and overall survival rates were 68.6% and 70.5%, respectively.Conclusion:Preliminary findings demonstrate that microwave hyperthermia combined with chemoradiotherapy achieve satisfactory outcomes and yield tolerable toxicity in patients with locally advanced gastric cancer.

目的 分析热疗联合放疗治疗晚期胰腺癌的临床疗效.方法 选择2017年1月—2018年4月我院收治的60例晚期胰腺癌患者为研究对象,随机分为两组,各30例.观察组患者给予热疗联合放疗,对照组给予放疗,比较两组患者的临床疗效及不良反应.结果 观察组放疗总有效率(63.33％)显著高于对照组(36.67％)(P=0.039);观察组疾病控制率(86.67％)显著高于对照组(63.33％)(P=0.037);观察组6个月、1年、2年总生存率分别为63.3％、46.7％和29.6％,均显著高于对照组的46.7％、30.0％和16.7％(P<0.05);观察组中位OS(11.5个月)显著长于对照组(5.8个月)(P=0.035);两组患者的不良反应发生率无明显差异(P>0.05).结论 热疗联合放疗可显著提高患者的放疗有效率和疾病控制率,有效延长其生存期,且治疗后毒副反应无明显增加,安全性较为可靠.

目前我国防控新型冠状病毒肺炎(简称新冠肺炎)虽已取得阶段性胜利,但目前全球疫情形势仍然严峻,境外输入性病例不断增加.肿瘤患者体质较弱属于新冠肺炎易感人群,在疫情的影响下,如何做好肿瘤患者防护,减少感染是医护人员及患者和家属面临的新的考验.结合自身临床经验,对新冠肺炎流行时期关于肿瘤患者的防控提出一些建议,旨在为患者在疫情下的防护和治疗提供参考.

目的:评价分析105例晚期肿瘤住院患者出现营养风险情况的相关因素.方法:选择2016年5月至2017年5月于我科就诊的105例晚期肿瘤住院患者作为此次的研究对象,运用营养风险筛查量表对所有患者出现营养风险情况进行评估.研究105例患者的病历,统计分析患者的住院时间、肿瘤位置以及典型症状,并分析患者住院时间与营养风险发生情况的相关性.统计分析两组患者的营养指标,并将统计分析的两组数据进行对比.结果:根据本文研究结果显示,105例患者中具有48.57%(51/105)的患者出现营养风险情况,其中56例消化系统癌患者出现营养风险情况(55.36%)概率最高;51例出现营养风险情况患者平均住院时间为(48.5±2.3)天.结论:晚期肿瘤住院患者中,消化系统癌患者更易出现营养风险情况,并且出现营养风险情况的患者往往相对于未出现营养风险情况的患者住院时间越长.